MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
0.8829
-0.0037
-0.42%
Pre Market: 0.9500 +0.0671 +7.60% 04:01 01/23 EST
OPEN
0.8975
PREV CLOSE
0.8866
HIGH
0.8990
LOW
0.8520
VOLUME
19
TURNOVER
0
52 WEEK HIGH
6.00
52 WEEK LOW
0.6986
MARKET CAP
38.53M
P/E (TTM)
-0.5612
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TPST last week (0113-0117)?
Weekly Report · 2d ago
Weekly Report: what happened at TPST last week (0106-0110)?
Weekly Report · 01/13 11:34
Tempest Therapeutics receives ODD from FDA for TPST-1120
TipRanks · 01/06 13:15
Tempest Receives Orphan Drug Designation From The U.S. FDA For Amezalpat To Treat Patients With Hepatocellular Carcinoma
Benzinga · 01/06 13:08
TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR AMEZALPAT TO TREAT PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
Reuters · 01/06 13:00
Weekly Report: what happened at TPST last week (1230-0103)?
Weekly Report · 01/06 11:44
Weekly Report: what happened at TPST last week (1223-1227)?
Weekly Report · 12/30/2024 11:37
Weekly Report: what happened at TPST last week (1216-1220)?
Weekly Report · 12/23/2024 11:44
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.